VA
RGC icon

Vident Advisory’s Regencell Bioscience RGC Stock Holding History

Vident Advisory’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.2K Sell
11,199
-18,389
-62% -$442K ﹤0.01% 1899
2026
Q1 		$752K Sell
29,588
-346
-1% -$9.79K 0.01% 1013
2025
Q4 		$629K Buy
29,934
+11,866
+66% +$193K 0.01% 1030
2025
Q3 		$279K Buy
+18,068
New +$259K ﹤0.01% 1429

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Amundi
Amundi Paris, France $416B AUM 44.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Vident Advisory's RGC Position: Q2 2026 in Review

Vident Advisory reduced its Regencell Bioscience (RGC) stake by 62% in Q2 2026, selling an estimated $442K and leaving 11,199 shares worth $68.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1899.

Vident Advisory first reported a position in RGC in Q3 2025 and has held it in 4 quarters since. The position peaked at $752K in Q1 2026. 35 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

  • Vident Advisory held 11,199 shares of Regencell Bioscience worth $68.2K as of Q2 2026.
  • Vident Advisory sold 18,389 Regencell Bioscience shares in Q2 2026, an estimated $442K.
  • Regencell Bioscience made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1899 holding.
  • Vident Advisory first reported a position in Regencell Bioscience in Q3 2025 and has held it in 4 quarters since.
  • Vident Advisory's Regencell Bioscience position peaked at $752K in Q1 2026.
  • 35 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.